Table 2.
Clinical Profile of Inflammatory Bowel Disease Patients in São Paulo City, Brazil
| Total (n=658) | CD (n=303) | UC (n=355) | p | |
|---|---|---|---|---|
| Disease duration (years) | ||||
| Mean ± SD | 9.8 ± 8.4 | 10.6 ± 9.2 | 9.2 ± 7.7 | 0.029* |
| Diagnostic delay (months) | ||||
| Median (Q1-Q3) | 13 (5–38) | 20 (6.5–48) | 11 (4–29) | <0.001* |
| Missing data (n) | 168 | 62 | 106 | |
| n (%) | ||||
| Family history of IBD | ||||
| Yes | 49 (8.2) | 26 (9.4) | 23 (7.1) | 0.358 |
| Missing data | 58 | 27 | 31 | |
| Hospitalization | ||||
| At least 1 since diagnosis | 438 (66.6) | 245 (80.9) | 193 (54.4) | <0.001* |
| Extraintestinal manifestations | ||||
| Joint | 326 (49.5) | 153 (50.5) | 173 (48.7) | 0.652 |
| Oral | 71 (10.8) | 44 (14.5) | 27 (7.6) | 0.004* |
| Skin | 31 (4.7) | 17 (5.6) | 14 (3.9) | 0.314 |
| Ocular | 29 (4.4) | 16 (5.3) | 13 (3.7) | 0.313 |
| Hepatobiliary disease | 26 (4) | 7 (2.3) | 19 (5.4) | 0.046* |
| Pharmacological treatment since diagnosis | ||||
| Corticosteroids | 498 (75.7) | 230 (75.9) | 268 (75.5) | 0.902 |
| Salicylates | 621 (94.4) | 267 (88.1) | 354 (99.7) | <0.001* |
| Immunomodulators | 406 (61.7) | 237 (78.2) | 169 (47.6) | <0.001* |
| Biologics | 236 (35.4) | 170 (56.1) | 66 (18.6) | <0.001* |
| Surgical Treatment | ||||
| At least 1 IBD-related surgery | 176 (26.7) | 160 (52.8) | 16 (4.5) | - |
Notes: Quantitative variables: Student’s t-test (normal distribution) and Mann–Whitney test (non-normal distribution); categorical variables: χ2 test; * p < 0.05 = statistical significance. IBD-related surgery: CD: abdominal or perianal procedures due to complications of disease; UC: partial or total colectomy.
Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis; SD, standard deviation; (Q1-Q3), interquartile range.